Nuwellis, Inc. (NUWE)

Nuwellis, Inc. (NUWE) Q2 2026 Earnings Call Prepared Remarks Transcript

Nuwellis Reports Second Quarter 2026 Financial Results and Business Highlights Focused on Double Digit Revenue Growth and Expanded Gross Margin

Nuwellis Strengthens Product Development Organization with Appointment of Dale Brady as Principal R&D Engineer

Nuwellis Announces Next-Generation Aquadex Platform Strategy to Expand Future Critical Care Applications

Nuwellis Announces Pricing of $3.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Nuwellis Announces Acceptance by Frontiers in Pediatrics of New Single-Center Retrospective Study Supporting Alternative Anticoagulation Strategy for Aquadex Ultrafiltration Therapy

Nuwellis Expands Pediatric Footprint with First Aquadex SmartFlow® Installations in Wisconsin

Nuwellis Announces Preliminary Revenue Results for the Second Quarter 2026 Showing Double Digit Growth

Nuwellis Awarded U.S. Patent for Novel Catheter Technology Designed to Enhance Extracorporeal Therapies

Nuwellis to Showcase Aquadex Therapy at KidneyBee Summit 2026

Nuwellis Celebrates Five Years of Support of the Pediatric Cardiac Critical Care Consortium (PC⁴)

Nuwellis Announces Pediatric Expansion in Michigan with First Aquadex SmartFlow® Installations

Incoming Nuwellis CEO Mike McCormick Underscores Strategic Priorities for Continued Market Expansion in Pediatric Category and Revenue Generation in Letter to Shareholders

Nuwellis Expands Critical Care Education with Aquadex Training at University of Minnesota Critical Care Cardiology Education Summit

Nuwellis Appoints Mike McCormick as Chief Executive Officer

Nuwellis Expands Collaboration with Major South Carolina Healthcare System to Install New Aquadex SmartFlow® Devices at One of its Children's Hospitals

Nuwellis Announces Closing of $6.0 Million Registered Public Offering

Nuwellis Announces Pricing of $6 Million Public Offering